Press Releases - Exact Sciences
6 days ago · News and events. Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts. View news and events
News and events | Exact Sciences
6 days ago · Exact Sciences is working to eradicate cancer by delivering a portfolio that gives providers the information they need to better serve their patients across the cancer care continuum — starting with familial risk.
Cancer Prevention, Screening & Therapy Guidance | Exact Sciences
Explore Exact Sciences, a leading provider of tests for cancer prevention, early detection and screening, and therapy guidance.
Investor Relations - Press Releases - Exact Sciences
News & Stories; Press Releases; Multimedia; Our Tests. Cologuard® OncoExTra™ Oncoguard® Liver; Oncotype DX® Oncotype DX Breast DCIS Score® Oncotype DX Breast Recurrence Score® Oncotype DX Colon Recurrence Score® Riskguard™ Pipeline & Data. Breast Radiation Score; Cologuard® 2.0; Colorectal Cancer Blood; LBgard® Blood Tubes ...
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
Jan 8, 2023 · Exact Sciences is a company that offers Cologuard and Oncotype DX tests for colorectal and breast cancer detection and treatment. The company announced its preliminary fourth quarter and full year 2022 results, with revenue growth …
Exact Sciences Announces Fourth Quarter 2023 Results
Feb 21, 2024 · Exact Sciences is a company that offers Cologuard® and Oncotype DX® tests for colorectal and breast cancer detection and treatment. The company reported record revenue and free cash flow for the fourth quarter and 2023, and expects 2024 revenue of $2.810-2.850 billion.
Cancerguard™ test | Exact Sciences
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts. View news and events FDA Approves Exact Sciences’ Cologuard Plus™ Test, Setting A New Benchmark in Non-Invasive Colorectal Cancer Screening
New England Journal of Medicine Publishes Cologuard ... - Exact …
Mar 13, 2024 · Cologuard Plus is a next-generation multitarget stool DNA test that detects colorectal cancer and advanced precancerous lesions with high sensitivity and specificity. The test significantly outperformed an independent fecal immunochemical test (FIT) in a 20,000-participant study published in The New England Journal of Medicine.
FDA Approves Exact Sciences’ Cologuard Plus Test
Oct 4, 2024 · Cologuard Plus is a next generation multitarget stool DNA test that detects colorectal cancer and precancer with higher sensitivity and lower false positives than Cologuard. The FDA-approved test is expected to launch in 2025 …
Exact Sciences Announces Third-Quarter 2024 Results
6 days ago · Exact Sciences is working to eradicate cancer by delivering a portfolio that gives providers the information they need to better serve their patients across the cancer care continuum — starting with familial risk.